tom.medsky.social profile picture

Thomas A. Nguyen DO @tom.medsky.social

I'm seeing a lot of big accounts missing the mark on this story. HHS through BARDA is cancelling contracts for mRNA vaccine research related to viral respiratory illnesses. This does not affect mRNA cancer research by NIH and Moderna.

It's still bad news but let's try to keep our facts straight.

Screen grab of a section of the HHS press release which is black text on white background. The wind-down affects a range of programs including:Termination of contracts with Emory University and Tiba Biotech.De-scoping of mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus.Rejection or cancellation of multiple pre-award solicitations, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others, as part of BARDA’s Rapid Response Partnership Vehicle (RRPV) and VITAL Hub.Restructuring of collaborations with DoD-JPEO, affecting nucleic acid-based vaccine projects with AAHI, AstraZeneca, HDT Bio, and Moderna/UTMB.
29

Replies

  1. tom.medsky.social profile picture

    Thomas A. Nguyen DO @tom.medsky.social

    We have bird flu vaccines from GSK, Sanofi, and CSL Seqirus. The first two are traditional egg based and the last one is cell based.

    I assume HHS is defending research for mRNA based flu vaccines, based on my reading of the press release.

    www.fiercepharma.com/manufacturin...

    CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have coll...

    GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply

    CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have coll...
    1